Prescription ·Strong evidence ·Reviewed May 2026
Rivaroxaban is a direct factor Xa inhibitor approved for stroke prevention in non-valvular atrial fibrillation, DVT/PE treatment and prevention, and secondary cardiovascular prevention (with aspirin in COMPASS trial). The ROCKET AF trial demonstrated non-inferiority to warfarin for stroke prevention in AF.
The bottom line
Evidence rating strong. Most-documented uses: non-inferior to warfarin for stroke prevention in af (rocket af), once-daily dosing for most indications, no routine monitoring required. 10 sources indexed (2012–2026), with 6 interaction records on file.
Core mechanism
Directly and selectively inhibits free and clot-bound factor Xa. Inhibition of factor Xa interrupts the intrinsic and extrinsic coagulation pathways, reducing thrombin generation and thrombus formation. High oral bioavailability and predictable pharmacokinetics. Partially renally eliminated (~33%).
15 mg and 20 mg doses MUST be taken with food to ensure adequate absorption (bioavailability increases from 66% to near 100%); 10 mg dose can be taken with or without food9
St. John's Wort potently induces CYP3A4 and P-glycoprotein, the primary metabolic pathways for rivaroxaban. This can substantially reduce rivaroxaban plasma concentrations, compromising anticoagulant efficacy and increasing thromboembolic risk.
Recommendation: Avoid combining St. John's Wort with rivaroxaban. Strong CYP3A4 inducers are listed as a contraindication in rivaroxaban prescribing information. Seek alternative supplements for mood support.
Curcumin has antiplatelet properties that may increase bleeding risk when combined with rivaroxaban. The additive effect on hemostasis through different mechanisms (antiplatelet + anticoagulant) poses a theoretical and potentially clinical risk of enhanced bleeding.
Recommendation: Use low-dose curcumin cautiously with rivaroxaban. Avoid high-dose curcumin supplements. Monitor for signs of unusual bleeding or bruising.
Fish oil has antiplatelet and antithrombotic properties that may increase bleeding risk when combined with rivaroxaban. The combination creates additive hemostatic impairment through different mechanisms. Higher fish oil doses pose greater risk.
Recommendation: Low-to-moderate dose fish oil (1-2g/day) can generally be used with rivaroxaban under medical supervision. Avoid doses above 3g/day. Monitor for signs of increased bleeding.
Ginkgo biloba is a potent platelet-activating factor (PAF) antagonist and has been linked in case reports to spontaneous intracranial, ocular, and postoperative bleeding. Added to rivaroxaban's factor Xa inhibition, the antiplatelet effect of ginkgo creates an additive bleeding risk.
Recommendation: Avoid ginkgo biloba while taking rivaroxaban. If you have been combining the two, stop the ginkgo and call your prescriber if you notice unusual bruising, nosebleeds, or any sign of bleeding.
Concentrated garlic extracts inhibit platelet aggregation and have been linked to perioperative bleeding. Added to rivaroxaban's factor Xa inhibition, the antiplatelet activity raises bleeding risk. Dietary garlic is not a concern.
Recommendation: Avoid concentrated garlic supplements (aged garlic extract, allicin capsules) while on rivaroxaban, and stop them at least 7 days before any planned surgery. Cooking with garlic is fine.
Nattokinase is a direct fibrinolytic enzyme that also reduces clotting factor levels. Combined with rivaroxaban's factor Xa inhibition, the additive effect substantially raises bleeding risk. Reports describe intracerebral and intra-abdominal hemorrhage with nattokinase plus other antithrombotics.
Recommendation: Do not combine nattokinase with rivaroxaban. If you have been taking both, stop the nattokinase and contact your prescriber, especially if you notice any unusual bruising or bleeding.
Numbered references. Citations throughout the page link here.
Wu X, Meng J, Yang Y et al.. Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis. Renal failure. 2026
Fredman D, McNeil R, Eldar O et al.. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies. Journal of thrombosis and thrombolysis. 2024
Netha A, Mazhar S, Azhar A et al.. Effectiveness of rivaroxaban in preventing cerebral venous thromboembolism: a systematic review and meta-analysis. Annals of medicine and surgery (2012). 2024
Mardi P, Abbasi B, Shafiee A et al.. Pharmacogenetic Approach for the Prevention of Rivaroxaban's ADRs: A Systematic Review and Meta-Analysis. Genetics research. 2023
Alves C, Batel-Marques F, Macedo AF. Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis. Journal of cardiovascular pharmacology and therapeutics. 2012
Rivaroxaban showed similar efficacy to standard anticoagulants for treatment of VTE in children with a trend toward fewer recurrent events and lower bleeding rates
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack